Studies suggest that the aberration of GRHL2 expression in cancer arises from genomic alterations, as GRHL2 resides in 8q22.3 region, which is frequently amplified in hepatocellular cancer (HCC), breast cancer, lung cancer, ovarian cancer and melanoma26, 27. This evidence concerns the gene GRHL2 and hepatocellular carcinoma.